Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.

Osteoporosis, one of the most prevalent metabolic bone diseases in developed countries, is a major public health problem through its association with fragility fractures. Several epidemiological studies have reported moderately increased risks of osteoporotic bone fractures in diabetic patients compared with general population. However, the underlying molecular link between diabetes and osteoporosis remains to be elucidated. In diabetes mellitus, the formation and accumulation of advanced glycation end products (AGEs) progress. There is a growing body of evidence to show that AGEs-their receptor (RAGE) interactions are involved in the development of atherosclerosis and diabetic microangiopathy. AGEs enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells. Furthermore, we have recently found that AGEs-RAGE interactions induced human mesenchymal stem cell apoptosis and subsequently prevented cognate differentiation into adipose tissue, cartilage, and bone. In vivo, serum levels of AGEs are elevated in patients with osteoporosis as well. These observations let us to hypothesize that AGEs could explain the molecular link between diabetes and osteoporosis. In this paper, we would like to propose the possible ways of testing our hypotheses. Does treatment with metformin, which has a potential effect on the inhibition of glycation reactions in vivo, decrease the risk for osteoporotic bone fractures in diabetic patients? If the answer is yes, is this beneficial effect of metformin superior to that of other anti-diabetic agents with equihypoglycemic properties? Does treatment with pyridoxamine, a post-Amadori inhibitor (so-called Amadorins) of AGE formation, reduce the risk for osteoporotic bone fractures as well? Furthermore, are increased levels of AGEs and RAGE in bone tissues associated with high risk for bone fractures in patients with diabetes? These clinical studies could clarify whether the AGEs-RAGE interactions serve as a causal link between diabetes and osteoporosis.

[1]  B. Szwergold,et al.  Metformin reduces systemic methylglyoxal levels in type 2 diabetes. , 1999, Diabetes.

[2]  R. Bouillon,et al.  Diabetic bone disease , 2007, Calcified Tissue International.

[3]  P. Vestergaard,et al.  Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk , 2005, Diabetologia.

[4]  G. Stein,et al.  Advanced glycation end-products pentosidine and N " -carboxymethyllysine are elevated in serum of patients with osteoporosis , 2003 .

[5]  S. Yamagishi,et al.  Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo. , 2004, Medical hypotheses.

[6]  C. Cooper,et al.  Diagnosis and epidemiology of osteoporosis , 2005, Current opinion in rheumatology.

[7]  M. Kayath,et al.  Prospective bone mineral density evaluation in patients with insulin-dependent diabetes mellitus. , 1998, Journal of diabetes and its complications.

[8]  S. Edelman,et al.  Osteoporosis and Diabetes , 2002, Current diabetes reports.

[9]  R. Bucala,et al.  Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[10]  T. Imaizumi,et al.  Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. , 2003, International journal of clinical pharmacology research.

[11]  A. Folsom,et al.  Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. , 2001, Diabetes care.

[12]  Z. Makita,et al.  Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. , 2002, Biochemical and biophysical research communications.

[13]  A. Schwartz,et al.  Diabetes Mellitus: Does it Affect Bone? , 2003, Calcified Tissue International.

[14]  L. Parsons Osteoporosis: incidence, prevention, and treatment of the silent killer. , 2005, The Nursing clinics of North America.

[15]  S. Yamagishi,et al.  Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. , 2004, Drugs under experimental and clinical research.

[16]  A. Schmidt,et al.  Atherosclerosis and diabetes: The rage connection , 2000, Current atherosclerosis reports.

[17]  R. Ziegler,et al.  AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. , 1998, Cardiovascular research.

[18]  A. Jenkins,et al.  Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions , 2000, The Journal of Biological Chemistry.

[19]  S. Yamagishi,et al.  TAGE (toxic AGEs) hypothesis in various chronic diseases. , 2004, Medical hypotheses.

[20]  Hiroshi Yamamoto,et al.  Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells , 1998, Diabetologia.

[21]  S. Kato,et al.  Advanced Glycation End‐Products Attenuate Human Mesenchymal Stem Cells and Prevent Cognate Differentiation Into Adipose Tissue, Cartilage, and Bone , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  T. Miyata,et al.  Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. , 1997, Journal of the American Society of Nephrology : JASN.